



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/34, 9/16, 9/50 A61K 9/00		A1	(11) International Publication Number: WO 94/08576 (43) International Publication Date: 28 April 1994 (28.04.94)
(21) International Application Number: PCT/EP93/02832 (22) International Filing Date: 14 October 1993 (14.10.93)		(74) Agents: BREWER, Christopher, Laurence et al.; Glaxo Holdings plc, Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).	
(30) Priority data: 9221760.3 16 October 1992 (16.10.92) GB 9221800.7 16 October 1992 (16.10.92) GB		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		(72) Inventors; and (75) Inventors/Applicants (for US only): DOUGLAS, Stephen, John [GB/GB]; EVANS, Jill [GB/GB]; Glaxo Group Research Limited, Park Road, Ware, Hertfordshire SG12 0DP (GB).	
(54) Title: TASTE-MASKING COMPOSITIONS OF RANITIDINE		<p><b>Published</b>  <i>With international search report.  Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p><b>(57) Abstract</b></p> <p>This invention relates to a composition which is substantially free of the bitter taste associated with ranitidine and comprises: a) a dispersion of lipid coated particles of ranitidine or a physiologically acceptable salt thereof in a non-aqueous vehicle; b) particles comprising ranitidine or a physiologically acceptable salt thereof incorporated into a core and coated with a lipid coating; c) lipid coated particles of a form of ranitidine which is poorly soluble in water; and processes for the preparation thereof and pharmaceutical compositions thereof.</p>			

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LK	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LY	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

**TASTE-MAKING COMPOSITIONS OF RANITIDINE**

The present invention relates to improvements in the formulation of the histamine H<sub>2</sub>-receptor antagonist ranitidine, particularly for oral administration.

Ranitidine, N-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methyl]-thioethyl]-N'-methyl-2-nitro-1,1-ethenediamine, and its physiologically acceptable salts are described and claimed in British Patent Specification No. 1565966, and a particular crystalline form of ranitidine hydrochloride is described and claimed in British Patent Specification No. 2084580B. In both these specifications there is reference to formulations for oral administration, which may take the form of for example tablets, capsules, granules, powders, solutions, syrups, suspensions, or tablets or lozenges for buccal administration. Oral preparations of ranitidine are also disclosed in British Patent Specification Nos. 2142820, 2198352, 15 2218336, 2219940, 2222772 and 2229094.

Oral administration constitutes a preferred route for administering ranitidine. Ranitidine, however, in common with many drug substances, has an inherently bitter taste, and this constitutes a disadvantage with certain types of oral preparation. Moreover, it is well known that patients may not complete a necessary course of medicine if they are prescribed an oral presentation which is particularly unpleasant to taste. The problems resulting from the bitter taste of ranitidine are particularly acute in formulations such as chewable tablets, granules, powders, solutions or suspensions. To some extent, the bitter taste may be masked by the use of sweetening and/or flavouring agents, although this is not entirely satisfactory, and an unpleasant after-taste may still remain in the mouth. In addition, there may be circumstances in which it is undesirable or inappropriate to use a sweetening and/or flavouring agent.

Various methods of taste-masking ranitidine have been described. For example, British Patent Specification No. 2218333 describes complexes formed between ranitidine and an ion exchange resin to give a resin adsorbate which is substantially free of the bitter taste associated with ranitidine.

Other methods of taste-masking ranitidine are described in EP349103, EP459695, EP473431 and US5084278.

We have now found that the bitter taste of ranitidine may be masked by coating the drug substance with a suitable lipid.

- 5 One of the factors that governs the degree of taste masking obtained by lipid coating is the water solubility of the input drug substance. Thus, for forms of ranitidine which are only poorly soluble in water (e.g. less soluble salts of ranitidine), the bitter taste associated with ranitidine may be satisfactorily masked by simple lipid coating of the drug substance. In the case of forms of  
10 ranitidine which are soluble in water to an appreciable extent (e.g. ranitidine base and certain of its salts), the degree of taste masking achieved by simple lipid coating of the drug substance may not be entirely satisfactory, particularly if the product is to be formulated in an aqueous medium or the product comes into contact with the wet environment of the mouth. We have found that the  
15 degree of taste masking achieved by coating the drug substance with a suitable lipid, especially when the ranitidine is in a form having an appreciable solubility in water, can be significantly enhanced if the drug substance is incorporated into a core prior to being coated with the lipid.
- 20 The resulting lipid coated particles, containing an inner core if required, are substantially insoluble in water but break down on contact with gastrointestinal fluid, such that the bitter taste associated with ranitidine is masked on oral administration, with subsequent release of the drug substance, by dispersion or dissolution, in the gastrointestinal tract.
- 25 Thus according to one aspect the present invention provides a composition which is substantially free of the bitter taste associated with ranitidine and comprises
- 30 a) a dispersion of lipid coated particles of ranitidine or a physiologically acceptable salt thereof in a non-aqueous vehicle  
b) particles comprising ranitidine or a physiologically acceptable salt thereof incorporated into a core and coated with a lipid coating

c) lipid coated particles of a form of ranitidine which is poorly soluble in water.

According to a further aspect, the present invention provides a composition for oral administration, which is substantially free of the bitter taste associated with ranitidine and comprises a dispersion of lipid coated particles of ranitidine or a physiologically acceptable salt thereof in a non-aqueous vehicle.

According to a yet further aspect, the invention provides a method of masking the bitter taste associated with ranitidine which comprises coating ranitidine or a physiologically acceptable salt thereof with a suitable lipid, and incorporating the lipid coated particles into a non-aqueous composition.

According to a yet further aspect the present invention provides particles for oral administration, comprising ranitidine or a physiologically acceptable salt thereof, optionally incorporated into a core, coated with a coating of a lipid, which particles are substantially free of the bitter taste associated with ranitidine.

According to a further aspect, the invention provides a method of masking the bitter taste of ranitidine which comprises coating ranitidine or a physiologically acceptable salt thereof, optionally incorporated into a core, with a suitable lipid.

Ranitidine may be employed according to the invention in the form of either its free base or a physiologically acceptable salt. Such salts include salts with inorganic or organic acids such as the hydrochloride, hydrobromide, sulphate, acetate, maleate, succinate, citrate, tartrate, fumarate and ascorbate salts. A particularly preferred salt of ranitidine is the hydrochloride.

Suitable lipids for the outer coating include fatty acids or monohydric alcohols thereof, fixed oils, fats, waxes, sterols, phospholipids and glycolipids either singly or in mixture. The lipid may, for example, be a high molecular weight (C<sub>10</sub> - C<sub>30</sub>) straight chain saturated or unsaturated aliphatic acid, such as palmitic or stearic acid; a mono- di- or tri- high molecular weight (C<sub>10</sub> - C<sub>30</sub>) aliphatic acid ester of glycerol, such as glyceryl tripalmitate, glyceryl tristearate or a mixed acid ester triglyceride; partially hydrogenated vegetable or animal oils such as hardened palm oil or hardened edible tallow; high molecular weight

(C<sub>10</sub> - C<sub>30</sub>) straight chain aliphatic alcohols such as stearyl alcohol or cetyl alcohol; microcrystalline waxes consisting of straight-chain, branched-chain or cyclic hydrocarbons with average molecular weight 580 to 900; or a mixture thereof. Mixtures of lipids may also be used, including mixtures of glyceryl esters of high molecular weight aliphatic acids such as mixtures involving glyceryl trilaurate, glyceryl tristearate, glyceryl tripalmitate and/or mixed acid ester triglycerides; mixtures of high molecular weight aliphatic acids such as mixtures of palmitic acid and stearic acid; mixtures of partially hydrogenated vegetable or animal oils and glyceryl esters such as hardened palm oil and glyceryl tripalmitate and mixtures of glyceryl esters with microcrystalline waxes such as glyceryl tripalmitate and microcrystalline wax. A particularly preferred lipid mixture is glyceryl tristearate in admixture with glyceryl trilaurate in a ratio in the range 9:1 to 1:4, more preferably 4:1 to 1:1, and in particular 3:1, by weight. The most preferred lipid is glyceryl tripalmitate of high purity having a low iodine value (preferably less than 1.0) and a low acid value (preferably less than 0.5).

The lipid coated particles of the invention will generally have a diameter of less than 1000 microns, preferably less than 500 microns, and more preferably less than 200 microns. Coated particles with a diameter in the range of 1-200 microns e.g. 20-150 microns are preferred. Control of the particle size is necessary to ensure that the subsequently formulated product does not produce a 'gritty' feel in the mouth and particles having a diameter of less than about 150 microns are preferred in this respect.

The lipid coated particles of the invention may conveniently be prepared by atomising a dispersion of ranitidine or a physiologically acceptable salt thereof, or a dispersion of core particles containing the ranitidine or ranitidine salt, as appropriate, in a molten lipid, and cooling the resultant particles, and such a process constitutes a further feature of the invention. Atomising techniques which may be used include the use of conventional atomisers such as rotary atomisers, pressure nozzles, pneumatic nozzles and sonic nozzles. The use of a two-fluid pneumatic nozzle atomiser fitted in a standard spray drying/chilling apparatus is particularly convenient.

In the atomisation process using a pneumatic two-fluid nozzle atomiser, the molten lipid dispersion will generally be supplied to the atomiser head at a temperature in the range of 60<sup>0</sup> to 90<sup>0</sup>C, preferably 70 to 80<sup>0</sup>C, the precise temperature depending on the particular lipid used. The atomising gas supplied to the nozzle may be air or an inert gas such as nitrogen. The temperature of the gas will generally be within the range 70 to 100<sup>0</sup>C, preferably 75 to 85<sup>0</sup>C with the precise temperature dependant upon the particular lipid material being used. It has been found that, in the coating process, the temperature at which the molten lipid dispersion is maintained is preferably in the range of 10 to 20<sup>0</sup>C above the melting point of the lipid. The atomising pressure is desirably controlled in order to produce particles of a preferred size.

The molten dispersion may be prepared by dispersing the ranitidine or ranitidine salt, or core particles containing the ranitidine or ranitidine salt, as appropriate, in the molten lipid or mixture of lipids using conventional techniques. When the input drug substance has not been incorporated into cores, a high shear mixer may be used. When the input drug substance has been incorporated into cores prior to lipid coating, a low shear mixer should be used, to avoid disruption of the cores. In general, the lipid or lipid mixture used for the outer coating should have a melting point within the range of 30 to 100<sup>0</sup>C, preferably 40 to 85<sup>0</sup>C, and the temperature of the molten lipid will be 10 to 20<sup>0</sup>C above its melting point. However, when overcoating cores which have been prepared by coating the input drug substance with a lipid or wax having a melting point which is higher than that of the outer lipid coating (as described hereinafter), the lipid or lipid mixture used for the outer coating preferably has a melting point of 40 to 60<sup>0</sup>C, and care must be taken not to allow the temperature of the mixture to rise above 10<sup>0</sup>C below the melting point of the lipid or wax used to form the core.

The ranitidine content of the lipid coated particles may be, for example, in the range of 1 to 80%, preferably 10 to 70%, more preferably 15 to 50% on a weight-to-weight (w/w) basis, the ranitidine being in the form of the free base or a physiologically acceptable salt, most preferably in the form of ranitidine hydrochloride.

- When the ranitidine is in a form which is soluble in water to an appreciable extent (e.g. in the form of ranitidine hydrochloride), such that it is necessary to incorporate the drug substance into inner cores prior to lipid coating, the final ranitidine content of the lipid coated particles will depend upon the input level of ranitidine in the core particles. When lipid coating cores containing the ranitidine or ranitidine salt, the cores may be dispersed in the molten lipid in an amount within the range of for example 1 to 80% by weight, preferably 20 to 70% by weight, and more preferably 30 to 60% by weight. The lipid provides the remainder of the weight of the molten dispersion.
- When it is necessary to incorporate the drug substance into inner cores, the cores for subsequent lipid coating, which constitute a further aspect of the invention, comprise a dispersion of the ranitidine or a physiologically acceptable salt thereof (e.g. ranitidine hydrochloride) in either a polymeric binder, or a lipid or wax having a melting point which is higher than that of the outer lipid coating.
- The cores are preferably spherical in shape and ideally have a particle size approaching that desired for the final lipid coated product. This allows the application of a discrete overcoat of lipid or mixture of lipids to each drug particle thereby fully encapsulating the drug core and satisfactorily masking the taste of ranitidine.
- Suitable polymeric binders for use in the drug cores include alkylcelluloses such as methylcellulose, ethylcellulose, propylcellulose; hydroxyalkylcelluloses (e.g. hydroxypropylcellulose or hydroxypropylmethylcellulose) and other cellulose based polymers (e.g. hydroxypropyl methylcellulose phthalate); polyvinylpyrrolidone; and polymer systems based on methacrylic acid or other acrylate polymers. Ethylcellulose is particularly preferred.
- Cores comprising ranitidine or a physiologically acceptable salt thereof and a polymeric binder may be prepared by spray drying a suspension of the drug substance dispersed in a solution of the polymer in a suitable solvent. A suitable solvent is one in which the polymer is soluble, but the ranitidine or ranitidine salt is essentially insoluble. Particularly suitable solvents include a mixture of dichloromethane and ethanol.

- The ratio of ranitidine to polymer in the suspension (the ranitidine being in the form of its free base or a physiologically acceptable salt) may be in the range 5:95 to 95:5, preferably 30:70 to 90:10, and more preferably 60:40 to 80:20, on a weight-to-weight (w/w) basis. The suspension or solution to be spray dried
- 5 should contain 5 to 80% w/w solids (i.e. ranitidine or ranitidine salt together with polymer) preferably 10 to 60% w/w and more preferably 20 to 40% w/w. A particularly preferred suspension for spray drying contains 20% w/w ranitidine hydrochloride suspended in a solution of 10% w/w ethylcellulose and 3% w/w ethanol in dichloromethane.
- 10 The suspension may be spray dried using a conventional spray drier. Atomisation of the suspension may be achieved using either a rotary atomiser, pressure nozzle, pneumatic nozzle or sonic nozzle. The use of a two fluid external mixing pneumatic nozzle is particularly convenient. In the spray drying process the inlet gas fed into the spray dryer is heated to a temperature
- 15 sufficient to remove the solvent from the droplets of atomised suspension or solution to produce spherical particles of the drug substance and the chosen polymer. For example, with a dichloromethane solvent system the temperature of the gas entering the chamber is preferably in the range 50 to 150<sup>0</sup>C, preferably 70<sup>0</sup>C to 120<sup>0</sup>C and more preferably 80<sup>0</sup>C to 100<sup>0</sup>C. In addition to
- 20 controlling the temperature of the chamber gas in the spray drying process it is necessary to control the feed rate and atomisation conditions for the suspension or solution to produce particles of the required shape and size. The preferred shape of the particles so formed is spherical. The presence of irregular shaped particles reduces the effectiveness of subsequent overcoating procedures in
- 25 masking the bitter taste of the drug. The size of the particles is also important. The particles preferably have a diameter of less than 200 microns, more preferably in the range 5 to 100 microns.
- In order to obtain lipid coated particles, or core particles for subsequent lipid coating, of the required size, it is necessary to reduce the particle size of the
- 30 input drug substance. This may be achieved using several techniques including fluid energy milling, hammer milling, pin milling and ball milling. The process of pin milling is preferred and may be used, for example, to reduce the particle size of ranitidine hydrochloride to less than 150 microns and preferably less than 100 microns. Alternatively the particle size may be reduced sufficiently during

the spray chilling procedure by high shear mixing of the molten mixture following dispersion of the input drug substance in the molten lipid(s). This may be achieved, for example, using a Silverson mixer fitted with a high shear square hole screen.

- 5      Where the cores for subsequent lipid coating comprise a dispersion of ranitidine or a physiologically acceptable salt thereof in a lipid or wax having a melting point which is higher than that of the outer lipid coating, the lipid or wax used for the core may have a melting point of for example 80°C or above, in order to prevent melting of the core during the subsequent lipid coating process.
- 10     Suitable lipids or waxes used in forming the cores include triglycerides of long chain saturated fatty acids; long chain fatty acids; long chain fatty alcohols; microcrystalline waxes consisting of straight-chain, branched-chain and cyclic hydrocarbons; or mixtures of these, suitably chosen (having regard to melting point) from the types of lipids listed previously. In the case of ranitidine hydrochloride, for example, the naturally occurring wax, carnauba wax, is particularly preferred.
- 15

The dispersion may be formed by melting the lipid or wax and raising the temperature of the molten material to 20°C to 30°C above its melting point. To this is then added the ranitidine or ranitidine salt of a suitably low particle size, to give a solids content in the molten dispersion of 20 to 80%w/w, preferably 40 to 70%w/w and more preferably 50 to 70% w/w. A particularly preferred dispersion comprises 60% w/w ranitidine hydrochloride in carnauba wax.

- 20     The molten dispersion is then spray chilled as described previously using atomising air heated to a temperature approximately 20 to 30°C above the melting point of the lipid or wax. Generally there is no need to chill the inlet air in the spray chiller. The product is collected as a free flowing powder using either a cyclone separator or bag filter. The particles are spherical in shape and have a particle size preferably less than 200 microns and more preferably in the range 5 to 100 microns.
- 25
- 30     Particularly preferred lipid coated particles according to the invention comprise cores consisting of ranitidine hydrochloride in an ethylcellulose matrix overcoated with glyceryl tripalmitate.

A preferred lipid coated product for suspension in a non-aqueous vehicle comprises particles of ranitidine hydrochloride coated with a mixture of glyceryl tristearate and glyceryl triauroate or, more preferably, with glyceryl tripalmitate.

The lipid coated particles of the invention may be incorporated into a pharmaceutical composition for oral administration, using one or more physiologically acceptable carriers or excipients.

The amount of ranitidine, preferably in the form of a physiologically acceptable salt, particularly ranitidine hydrochloride, in the oral formulation is preferably in the range of 10 to 800mg per dosage unit, e.g. 20 to 600mg, more preferably 25 to 300mg, such as 25, 75, 125 or 150mg, expressed as the weight of free base.

The unit dose may be administered up to, for example, 6 times a day depending upon the unit dose used, the nature and severity of the conditions being treated, and the age and weight of the patient. Thus, for example, in the treatment of minor conditions where there is an advantage in lowering gastric acidity such as, for example, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn, gastritis and dyspepsia, lower and more frequent doses of ranitidine may be used, for example doses in the range of 10-150mg, e.g. 25-75mg ranitidine expressed as the weight of free base, administered up to 6 times a day as and when required. For more serious conditions such as duodenal and gastric ulceration, reflux oesophagitis and Zollinger-Ellison syndrome, higher and less frequent doses of ranitidine will be employed, for example 75-600mg, e.g. 150mg unit doses administered one to four, preferably once or twice, daily.

The compositions according to the invention may for example take the form of tablets, capsules, granules, powders, tablets or lozenges for buccal administration, or liquid preparations such as suspensions. Chewable or suckable tablets, granules, and suspensions represent particularly preferred dosage forms. Granules may be ingested directly, taken with for example a draught of water, or dispersed in water (if the ranitidine is in a form which is poorly soluble in water) or other suitable vehicle prior to administration. The suspensions may be non-aqueous and, in the case of forms of ranitidine which

are poorly soluble in water, the lipid coated material may also be formulated as an aqueous suspension.

5 The pharmaceutical compositions according to the invention, comprising a dispersion of lipid coated particles of ranitidine or a physiologically acceptable salt thereof in a non-aqueous vehicle, formulated for oral administration, may be presented in the form of, for example, non-aqueous suspensions, chewable soft gelatin capsules, or chewable tablets. Non-aqueous suspensions are preferred.

The compositions may be formulated using conventional pharmaceutically acceptable carriers or excipients.

10 Thus for example granules may be prepared by granulating the lipid coated particles with a binding agent using well known pharmaceutical granulation techniques, more particularly fluidised bed granulation. Suitable binding agents include an alkylcellulose or polyvinylpyrrolidone, more preferably hydroxypropylmethylcellulose. It may also be beneficial to add a small amount 15 of a pharmaceutically acceptable surface active agent (e.g. sodium lauryl sulphate) to the granulating fluid to aid the wetting of the particles. The granules are dried using conventional pharmaceutical drying techniques taking care not to allow the temperature of the granules to rise to within about 10°C of the melting point of the outer lipid coating.

20 Tablets of the lipid coated particles may be obtained by compressing the granules. Alternatively a dry mix of the various excipients used for granule formation could be compressed together with suitable binding agents e.g. polyvinylpyrrolidone. Chewable tablets may be prepared incorporating the lipid coated particles with a suitable chewable base such as sucrose, glucose, lactose, maltose or a mixture thereof, preferably sucrose, according to conventional procedures. Cast chewable tablets may be prepared by incorporating the lipid coated particles into low melting point fatty bases. The chosen fatty base should have a melting point that is sufficiently high to give a solid tablet at room temperature and preferably at temperatures up to 30°C but 25 not too high so as to cause melting of the outer lipid coating during processing or to reduce the bioavailability of the drug. Suitable bases are for example macrogols, fatty acids, mono- di- and tri-glycerides, alkanes, and fatty alcohols 30

either alone or in admixture. In the case of ranitidine hydrochloride, for example, particularly preferred fatty bases are suppository bases which melt at about 37°C and are pharmaceutically acceptable e.g. hard fat and theobroma oil.

- 5      Suitable non-aqueous vehicles for use in the compositions according to the invention, particularly non-aqueous suspensions and chewable soft gelatin capsules, include fractionated coconut oil fractionated coconut oil cross-linked with an organic acid such as succinic acid, arachis oil, sesame oil, soya oil and other animal vegetable or synthetic oils suitable for oral administration, used  
10     either singly or in admixture.

Aqueous suspensions may be obtained by dispersing the lipid coated particles in an aqueous vehicle. Suitable vehicles include sucrose syrup; hydrogenated sucrose syrup; sorbitol solution and concentrated solutions of other sugars; aqueous solutions thickened with cellulose based polymers such  
15     as hydroxypropylmethyl cellulose, methylcellulose or microcrystalline cellulose in suspension; aqueous solutions thickened with polysaccharides such as starch; aqueous solutions thickened with polyacrylates such as carbopol; and aqueous solutions thickened with colloidal dispersing agents such as magnesium aluminium silicate. Various pharmaceutically acceptable excipients  
20     such as preservatives and buffer salts may also be included. In addition, surface active agents may be added to aid wetting of the lipid coated particles.

The various preparations may also contain bulk sweeteners (e.g. sucrose), intense sweeteners (e.g. sodium saccharin or aspartame) and/or flavouring agents as appropriate.

- 25     The compositions according to the invention may, if desired, be administered in combination with one or more other therapeutic agents, for example the compositions may also contain a suitable antacid such as calcium carbonate.

The following Preparations 1 and 2 illustrate the preparation of core particles according to the invention containing ranitidine hydrochloride. Ranitidine in the form of its free base or a physiologically acceptable salt may be incorporated  
30     into cores in a similar manner.

Preparation 1

Ethylcellulose (250g) was dissolved in dichloromethane (1000g) containing ethanol (72g). To this was added ranitidine hydrochloride (500g) of a low particle size (less than 100 microns) dispersed in dichloromethane (780g). The suspension was mixed under high shear until homogeneous, and then pumped into a spray drier at a flow rate of approximately 260g/minute and atomised using an external mixing two-fluid pneumatic nozzle (dimensions 80/150/180 thousandths of an inch) with an atomising air pressure of 60psi. The temperature of inlet air into the chamber was 850C. The product was collected using a cyclone separator and was composed of mostly spherical particles in the size range 1 to 300 microns with most of the material having a particle diameter of less than 200 microns.

15 Preparation 2

Carnauba wax (prime yellow grade) (400g) was melted and heated to 1000C. To this was added milled ranitidine hydrochloride (600g) of a low particle size (less than 100 microns) and this was dispersed by mixing with a paddle. The molten dispersion at 1000C was spray chilled at a rate of approximately 500g/minute using an internal mixing two-fluid pneumatic nozzle fed with atomising air at a pressure of 60psi and a temperature of 1000C. The solidified product was collected and found to comprise spherical particles up to 300 microns in diameter. Particles greater than 200 microns were removed by sieving.

25

The following Examples 1, 2 and 3 illustrate the preparation of lipid coated particles according to the invention, in which cores as described in Preparations 1 and 2 are overcoated with lipid.

Example 1

Glyceryl tristearate (525g) and glyceryl tri laurate (175g) were melted together and raised to a temperature of 75°C. To the molten lipids was added spray dried ranitidine hydrochloride-ethylcellulose core particles (300g) containing 5 66.6%w/w ranitidine hydrochloride. The molten dispersion was mixed to give a homogeneous suspension and pumped into a spray dryer/chiller apparatus (chamber height 2m) at a rate of approximately 500g/minute and atomised using an external mixing two-fluid pneumatic nozzle (with nozzle dimensions 100/150/180 thousandths of an inch) and atomising air at a temperature 10 approximately 20°C above the melting point of the lipid mixture and an atomising pressure of 60psi. The product was chilled using air fed into the spray chamber at a temperature of 140°C and the solid product collected in a cyclone separator. The product had a particle size range of 1-300 microns with the majority of the particles with diameters less than 200 microns. The final 15 ranitidine hydrochloride content was 20%w/w and the material was substantially tasteless.

Example 2

Glyceryl tripalmitate (200g) was melted and raised to a temperature of 72°C. 20 To this was added ranitidine hydrochloride- carnauba wax core particles (100g) containing 60%w/w ranitidine hydrochloride. The core particles were mixed in using a paddle to give a homogeneous suspension and the temperature of the dispersion maintained at 72°C. The molten dispersion was then spray chilled at a rate of about 500g/minute as detailed above using an internal mixing two-fluid 25 pneumatic nozzle with an atomising air pressure of 60psi and temperature of 73°C. The resulting particles had a particle size range of about 1 to 300 microns with the majority of the particles having diameters less than 200 microns. The final ranitidine hydrochloride content was 20%w/w and the material was substantially tasteless.

30

Example 3

- Glyceryl tripalmitate (350g) was melted and raised to a temperature of 75°C. To the molten lipid was added spray dried ranitidine hydrochloride-ethylcellulose core particles (150g) containing 66.6%w/w ranitidine hydrochloride. The molten dispersion was mixed to give a homogeneous suspension and pumped into a spray dryer/chiller apparatus (chamber height 2m) at a rate of approximately 500g/minute and atomised using an external mixing two-fluid pneumatic nozzle (with nozzle dimensions 100/150/180 thousandths of an inch) and atomising air at a temperature approximately 20°C above the melting point of the lipid mixture and an atomising pressure of 60psi.
- 5 The product was chilled using air fed into the spray chamber at a temperature of 140°C and the solid product collected in a cyclone separator. The product had a particle size range of 1-300 microns with the majority of the particles with diameters less than 200 microns. The final ranitidine hydrochloride content was 20%w/w and the material was substantially tasteless.
- 10 The following Examples 4 and 5 illustrate the preparation of lipid coated particles of ranitidine hydrochloride. Other physiologically acceptable salts, or ranitidine in the form of its free base, may be lipid coated in a similar manner, using suitably chosen lipid(s).
- 15

Example 4

- 20 Glyceryl tripalmitate (1200g) was melted and raised to a temperature of 75°C. To this was added milled ranitidine hydrochloride (300g). The molten dispersion was mixed to give a homogenous suspension and pumped to a spray drier/chiller apparatus (chamber height 2m) at a rate of approximately 500g/minute. The mixture was atomised using an external mixing two-fluid pneumatic nozzle (with nozzle dimensions 80/150/180 thousandths of an inch) and atomising air at a temperature approximately 300°C above the melting point of the lipid and an atomising pressure of 50psi. The atomised droplets were chilled using air fed into the spray chamber at a temperature of 10°C and the solid product collected in a cyclone separator. The product comprised spherical particles with a median particle size of 120 microns.
- 25
- 30

Example 5

Glyceryl tristearate (900g) and glyceryl tri laurate (300g) were melted together and raised to a temperature of 75°C. To this was added ranitidine hydrochloride (300g). The molten dispersion was subjected to high shear mixing using a Silverson high shear mixer for 10 minutes to reduce the ranitidine hydrochloride particle size. This mixture was spray chilled as described in Example 4, to give a product having a similar particle size and shape.

The following Examples A, B, C and D illustrate pharmaceutical compositions according to the invention in which the lipid coated particles are in particular as described in Examples 2 and 3 above. Other types of lipid coated particles according to the invention, containing an inner core into which is incorporated ranitidine free base or another water-soluble physiologically acceptable salt thereof may be formulated in a similar manner.

15      Example A    Flavoured Granules

(i) Lipid coated ranitidine hydrochloride \*    75g

Xylitol (powdered)    120g  
Flavour (peppermint)                  2g  
20      Granulating fluid \*\*                30ml

\*      Contains 20%w/w ranitidine hydrochloride as a ranitidine hydrochloride - carnauba wax core overcoated with glyceryl palmitate.

\*\*     10%w/v solution of hydroxypropylmethyl cellulose (3 centipoise grade) in ethanol (85%)/water (15%) mixture.

## 16

The solids were mixed and fluidised in a fluid bed granulator. The temperature of the bed was raised to 40°C and the granulating fluid sprayed onto the bed. The resulting granules were dried and screened (1.0mm sieve). Each 2.24g of granules contained 168mg ranitidine hydrochloride (equivalent to 150mg ranitidine free base) and may be taken dry or first dispersed in water.

5

	(ii) Lipid coated ranitidine hydrochloride*	75g
	Xylitol (powdered)	120g
	Flavour (peppermint)	2g
10	Granulating fluid**	30ml

15

\* Contains 20% w/w ranitidine hydrochloride as a ranitidine hydrochloride-ethylcellulose core overcoated with glyceryl tripalmitate.

\*\* 10% w/w solution of hydroxypropylmethyl cellulose (3 centipoise grade) in ethanol (85%)/water (15%) mixture.

The granules were formed as described in Example A (i).

20

Example B Compressed Chewable Tablets.

25

The granules produced in Examples A(i) and A(ii) were mixed with 0.5%w/w magnesium stearate and then compressed using a conventional pharmaceutical tablet press. Each tablet weighed 2.24g and contained 168mg ranitidine hydrochloride (equivalent to 150mg ranitidine free base).

Example C Cast Chewable Tabletper tablet

5       Lipid coated ranitidine hydrochloride \*   0.84g  
Witepsol H15 \*\*     1.8g  
Theobroma oil BP   0.36g  
Aspartame   0.01g  
Flavour      0.005g

10

\* Contains 20%w/w ranitidine hydrochloride as a ranitidine hydrochloride-ethylcellulose core overcoated with glyceryl tripalmitate.

15       \*\* Triglyceride suppository base manufactured by Dynamit Nobel.

20       The Witepsol H15 and theobroma oil were melted together and heated to 36°C. The solids were incorporated and the molten mixture cast into tablet shaped moulds. After solidification the tablets were removed. Each tablet weighed about 3g and contained 168g ranitidine hydrochloride.

Example D Non-aqueous Suspension

	Lipid coated ranitidine hydrochloride *	16.8g
	Xylitol (powdered)	18.0g
	Aspartame	2.0g
5	Flavour	q.s.
	Fractionated coconut oil	to 100ml

- \* Contains 20%w/w ranitidine hydrochloride as a ranitidine hydrochloride-ethylcellulose core overcoated with glyceryl tripalmitate.

15 The lipid coated ranitidine hydrochloride, xylitol, aspartame and flavour were added to the bulk of the fractionated coconut oil and mixed using a Silverson mixer fitted with a low shear head. The suspension was then made up to volume with fractionated coconut oil and mixed to give a homogenous suspension. The dose of ranitidine hydrochloride was 168mg per 5ml.

20 The following Examples E, F and G illustrate non-aqueous pharmaceutical compositions according to the invention, in which the lipid coated material is in particular as described in the above Examples 4 and 5. Other lipid coated materials formed by coating ranitidine or a physiologically acceptable salt thereof with other types of lipid(s) may be formulated in a similar manner.

Example E Non-aqueous suspension

(i) For 100ml

- Glyceryl tripalmitate coated ranitidine hydrochloride (containing 20% w/w ranitidine hydrochloride) 16.8g
- 5 Aspartame 2.0g
- Mannitol (powdered) 18.0g
- Flavour q.s.
- Fractionated coconut oil to 100ml
- 10 The lipid coated ranitidine hydrochloride, mannitol, aspartame and flavour were added to the bulk of the fractionated coconut oil and mixed using a Silverson mixer fitted with a low shear head. The suspension was then made up to volume with fractionated coconut oil and mixed to give a homogenous suspension. The dose of ranitidine hydrochloride was 168mg per 5ml (equivalent to 150mg free base).
- 15

(ii) For 100ml

- Ranitidine hydrochloride (20%w/w) coated with a 3:1 mixture of glyceryl tristerate and glyceryl trilaurate 16.8g
- 20 Xylitol (powdered) 18.0g
- Aspartame 1.5g
- Flavour q.s.

20

Fractionated coconut oil to 100ml

The suspension was prepared by the method described in  
Example E(i).

5

Example F Chewable soft gelatin capsule

per capsule

Ranitidine hydrochloride (30%w/w) coated

with glyceryl tripalmitate 0.56g

10 Aspartame 0.03g

Flavour q.s.

Fractionated coconut oil 0.7g

The ingredients are mixed, and the mixture filled into soft gelatin capsules.

Example G Cast chewable tabletper tablet

Glyceryl tripalmitate coated ranitidine

5 hydrochloride (containing 20% w/w

ranitidine hydrochloride) 0.84g

Witepsol H15\* 1.8g Theobroma oil BP 0.36g

Aspartame 0.01g

Flavour 0.05g

10

\* Triglyceride suppository base manufactured by Dynamit Nobel.

- 15 The Witepsol H15 and theobroma oil are melted together and heated to 36°C. The solids are incorporated and the molten mixture cast into tablet shaped moulds. After solidification the tablets are removed. Each tablet weighs about 3g and contains 168g ranitidine hydrochloride (equivalent to 150mg free base).

**Claims**

1. A composition which is substantially free of the bitter taste associated with ranitidine and comprises
  - a) a dispersion of lipid coated particles of ranitidine or a physiologically acceptable salt thereof in a non-aqueous vehicle
  - b) particles comprising ranitidine or a physiologically acceptable salt thereof incorporated into a core and coated with a lipid coating
  - c) lipid coated particles of a form of ranitidine which is poorly soluble in water.
2. A composition as claimed in claim 1 wherein the lipid is a mono-, di- or tri-<sub>C<sub>10</sub>-C<sub>30</sub></sub> aliphatic ester of glycerol or a mixture thereof.
3. A composition as claimed in claim 2 wherein the lipid mixture comprises glyceryl tristearate in admixture with glyceryl trilaurate in a ratio in the range 9:1 to 1:4.
4. A composition as claimed in any of claims 1 to 3 wherein the particles have diameters in the range of 1 - 200 microns.
5. A composition as claimed in any of claims 1 to 4 wherein the ranitidine content of the particles is in the range of 10 to 70% w/w, the ranitidine being in the form of the free base or a physiologically acceptable salt thereof.
6. A composition as claimed in any of claims 1 to 5 containing ranitidine hydrochloride.
7. A process for the preparation of a composition as claimed in claim 1 which comprises dispersing particulate ranitidine, or a physiologically acceptable salt thereof, or core particles containing the ranitidine or the ranitidine salt, in a molten lipid, atomising the dispersion and cooling and collecting the coated particles thereby obtained.
8. A pharmaceutical composition for oral administration comprising a composition as claimed in any of claims 1 to 6, or as prepared by a process as

claimed in claim 7, together with one or more physiologically acceptable carriers or excipients.

9. A pharmaceutical composition as claimed in claim 8 in the form of chewable or suckable tablets, chewable soft gelatin capsules, suspensions or granules.
- 5      10. A pharmaceutical composition as claimed in claim 8 or claim 9 containing 10 to 800mg ranitidine per dosage unit, expressed as the weight of free base.

## INTERNATIONAL SEARCH REPORT

Intern: ai Application No  
PCT/EP 93/02832

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 A61K31/34 A61K9/16 A61K9/50 A61K9/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbol)  
IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	CA,A,2 068 366 (MORELLA A. ET AL) 11 November 1992 see, page 2, line 39 - page 3, line 11 see page 8, line 2 - line 20 see page 12, line 5 - line 23 see page 19 - page 20; example 4 see page 22 - page 23; example 7 ---	1,4-10
X	FR,A,2 643 263 (GLAXO CANADA INC) 24 August 1990 see page 3, line 1 - page 4, line 23 see page 6, line 13 - line 15 see page 7, line 1 - line 14 see page 7 - page 8; example 1 ---	1,2,5,6, 8-10
Y	---	2,4,9

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or sale made public before the international filing date
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
\*Z\* document member of the same patent family

Date of the actual completion of the international search

27 January 1994

Date of mailing of the international search report

15.02.94

Name and mailing address of the ISA

Europ. Patent Office, P.B. 5818 Patenttaan 2  
NL - 2200 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Boulois, D

## INTERNATIONAL SEARCH REPORT

Intern. Application No  
PCT/EP 93/02832

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 257 368 (AMERICAN CYANAMID COMPANY) 2 March 1988 see page 4; example 1 see page 7 - page 12; table II ---	2,4
Y	GB,A,2 204 792 (GLAXO GROUP LTD) 23 November 1988 see page 7, line 12 - line 21 see page 13, line 6 - line 9 see page 17 - page 18; examples 5,6 ---	2,4
Y	GB,A,2 218 333 (GLAXO GROUP LTD) 15 November 1989 cited in the application see page 13 - page 14; examples 12-14 ---	9
A	EP,A,0 322 048 (SMITH KLINE DAUELSBERG GMBH) 28 June 1989 see page 4 - page 5; example 1 ---	1-10
A	WO,A,92 04893 (SMITH KLINE BEECHAM CORPORATION) 2 April 1992 see page 2, line 18 - page 3, line 12 ---	1
P,X	WO,A,92 21328 (AFFINITY BIOTECH INC) 10 December 1992 see page 14; example 6 ---	1
A	EP,A,0 273 890 (ASTRA LAKEMEDEL AKTIEBOLAG) 6 July 1988 see page 7 - page 8; examples 3,4 ---	1
A	EP,A,0 421 581 (WARNER LAMBERT COMPANY) 10 April 1991 see page 18 - page 19; example 1 see page 21 - page 22; example 3 -----	1-4

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. Application No.

PCT/EP 93/02832

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
<b>CA-A-2068366</b>			<b>NONE</b>
FR-A-2643263	24-08-90	AU-B- 629303 AU-A- 5007390 CH-A- 680567 DE-A- 4005650 GB-A,B 2229094 JP-A- 3200728 LU-A- 87681 NL-A- 9000428 SE-A- 9000625 US-A- 5028432	01-10-92 30-08-90 30-09-92 06-09-90 19-09-90 02-09-91 08-10-91 17-09-90 24-08-90 02-07-91
EP-A-0257368	02-03-88	AU-B- 597708 AU-A- 7672587 CA-A- 1296627 DE-A- 3777721 JP-A- 63048223 US-A- 4837381 ZA-A- 8705898	07-06-90 18-02-88 03-03-92 30-04-92 29-02-88 06-06-89 12-02-88
GB-A-2204792	23-11-88	AU-B- 607996 AU-A- 1615788 BE-A- 1000956 CH-A- 675357 DE-A- 3816464 FR-A- 2615101 JP-A- 63303928 NL-A- 8801236 SE-B- 466047 SE-A- 8801813 US-A- 4865851	21-03-91 17-11-88 23-05-89 28-09-90 24-11-88 18-11-88 12-12-88 01-12-88 09-12-91 15-11-88 12-09-89
GB-A-2218333	15-11-89	AU-B- 624613 AU-A- 3461789 BE-A- 1002159 CH-A- 679011 DE-A- 3915347 FR-A- 2631232 JP-A- 2111719	18-06-92 16-11-89 14-08-90 13-12-91 16-11-89 17-11-89 24-04-90

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. Application No.

PCT/EP 93/02832

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A-2218333		LU-A- 87515 NL-A- 8901188 SE-A- 8901671 US-A- 5032393 US-A- 5219563	12-06-90 01-12-89 12-11-89 16-07-91 15-06-93
EP-A-0322048	28-06-89	AU-B- 605671 AU-A- 2915789 DE-A- 3872199 WO-A- 8905640 JP-T- 2502729 US-A- 5057319	17-01-91 19-07-89 23-07-92 29-06-89 30-08-90 15-10-91
WO-A-9204893	02-04-92	AU-A- 8546591 EP-A- 0548238	15-04-92 30-06-93
WO-A-9221328	10-12-92	AU-A- 2146792	08-01-93
EP-A-0273890	06-07-88	AU-B- 609753 AU-A- 8199187 CA-A- 1317883 DE-A- 3785167 JP-A- 63166838 US-A- 5085868	09-05-91 23-06-88 18-05-93 06-05-93 11-07-88 04-02-92
EP-A-0421581	10-04-91	AU-A- 6367890 CA-A- 2026707 JP-A- 3188018	11-04-91 04-04-91 16-08-91